NEW YORK, Dec. 4—Myriad Genetics and Laboratory Corporation of America Holdings announced Tuesday that LabCorp will be the genomics company’s exclusive sales and distribution partner in the US, and will market the company’s DNA-based  tests to its network of more than 200,000 primary care physician customers.

The marketing alliance covers all four of Myriad’s predictive tests, which detect common mutations in order to assess patient risk for hypertension, cardiovascular disease and certain hereditary cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.